arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

QuidelOrtho Corp

QDEL
$12.29 ▼ -4.05 (-24.76%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
23 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

QuidelOrtho Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $838.2M
Dividend Yield
Revenue Growth -10.5%
Op. Margin -5.1%
ROIC -2.0%
FCF / Share $-0.98
Trailing P/E
Price / Book 0.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

23-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$619.80M
↓ -10.5%
Net Income Profit after all expenses
$-91.80M
↓ -622.8%
Operating Margin Operating profit as % of sales
-5.1%
↑ +44.0% 7th
FCF / Share Free cash flow per share
$-0.98
↑ +29.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
11
Returns
14
Financial Health
27
Cash Quality
25

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 23 quarters